Stock detail
Celcuity (CELC) stock price, chart, and key data
View Celcuity stock price, chart movement, and headline metrics on Woodstock's stock detail page.
Stock detail
Celcuity
CELC · XNAS
$83.60
-7.19%
-$6.48
Key metrics
52-week range
$7.00 - $1.00
Close price
$90.08
Market cap
$4.4B
P/E ratio
-62.56
Beta
0.5
About the company
Celcuity Inc
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
Analyst rating summary
A current read on analyst sentiment from the insight feed.
Mean target
$161
10
Buy
/ 10
Recent calls
08/18/2026
Craig-Hallum
Chase Knickerbocker
Buy · Price target $173
08/16/2026
Guggenheim
Bradley Canino
Buy · Price target $175
08/14/2026
LifeSci Capital
Oliver McCammon
Buy · Price target $165
Ticker holders
Review politician disclosures and insider transactions in tabs.
No holder data is available for this category yet.
24/5 Trading
Act on the stock when the timing works for you.
With Woodstock, you can move from chart review to order placement in one flow. Trade eligible US stocks 24/5, even outside regular market hours.
*24-hour trading is available except during system maintenance. Some stocks are not eligible for extended-hours trading.
Download the app